The headline combines different promises
A collaboration announcement can contain a large and precisely stated potential value. The precision is attractive: it makes a complex arrangement easy to discuss and gives business-development colleagues a visible result after a long negotiation. Yet the total may combine an upfront receipt with later payments that require different events and may never occur. Those components can all be legitimate parts of the agreement. Finance's responsibility is to ensure that their presentation does not turn a conditional commercial opportunity into authority to spend cash the company has not received.
One Velmara agreement provided USD12 million upfront and up to USD48 million tied to specified later development events. The potential total was USD60 million. The collaboration team had negotiated access, responsibilities and economic terms it considered valuable, and the board needed to understand that achievement. At the same time, the current portfolio could not be planned as though USD60 million had arrived. The future amounts depended on conditions that required scientific work and other events. A signed contract gave those possibilities a legal structure; it did not make the underlying outcomes certain.
I began by asking for a plain account of each payment condition and the work associated with it. Business-development and legal colleagues supplied the contractual interpretation. Scientific and operating leaders explained what had to happen in practice. Finance connected those accounts to cash scenarios and the company's existing resources. We did not replace the agreement with a simplified finance label. The point was to make the distinction usable for management while retaining access to the specialists who could explain the terms and responsibilities accurately.
The initial internal presentation emphasised the USD60 million potential value. Negotiating colleagues worried that a more qualified cash account would diminish the achievement. I understood the concern because reducing a complex transaction to the upfront receipt alone would also be misleading. We therefore kept the full opportunity in the commercial narrative and separated it from the funding view. The board could consider the strategic value of the collaboration while seeing exactly which amounts were available, which were conditional and which operating commitments accompanied the agreement.
Build the unconditional plan first
The USD12 million entered the cash plan when it was received. The later USD48 million appeared in separately described scenarios rather than the unconditional funding base. This did not mean we assumed the future payments would fail. It meant that management's immediate commitments needed an account that remained intelligible without them. The company could still choose to accept a dependency, but directors should make that choice knowingly. Hiding it inside an aggregate agreement value would deprive the board of the opportunity to assess the exposure and possible alternatives.
The receipt also came with work to do. We allocated USD3.1 million to near-term collaboration activity identified in the operating plan. The balance remained part of the wider company cash forecast, where other responsibilities and costs still mattered. Subtracting USD3.1 million from USD12 million would not establish the agreement's accounting profit or show that the remainder was unrestricted surplus. The allocation was a management funding decision within a larger enterprise. It needed to be understood alongside the contract's continuing requirements and the company's other commitments.
Accounting revenue recognition was a separate assessment. The receipt date, the headline consideration and the internal work budget each provided information, but none alone settled the reporting treatment. Qualified finance and legal colleagues considered the agreement in the relevant accounting context. In a public leadership account, I would avoid presenting that particular assessment as a general rule for every collaboration. Different obligations and terms can lead to different conclusions. The useful lesson is that commercial value, cash and recognised revenue should not be treated as interchangeable descriptions merely because they relate to one transaction.
The scenarios also needed a timetable. A later payment might arrive after a substantial period of work, leaving the company to fund the intervening activity. A programme could require additional resources before reaching the event specified in the contract. We asked whether the cash plan made those gaps visible and what choices would be available if timing moved. This was not a reason to reject a promising partnership. It was a way to ensure that the company could perform its responsibilities without depending on a payment schedule that the agreement did not actually promise.
Let commercial success keep its qualifications
The board approved the collaboration with a clearer distinction between its immediate funding effect and potential future economics. At the point described, USD12 million had been received and the later USD48 million had not. Those facts remained visible in subsequent discussion. We did not report the maximum as a forecast or present a later internal allocation as proof that the whole transaction had already earned a particular return. The commercial team could explain the opportunity without having to defend financial claims the agreement could not support.
A useful internal vocabulary makes this easier. I want colleagues to distinguish upfront receipt, potential consideration, expected cash and recognised revenue before a negotiation reaches its final stage. Waiting until the board paper is almost complete turns a necessary clarification into an argument about whether finance is supportive. Agreement on the language allows each function to retain its contribution: commercial leadership explains the opportunity, scientific teams explain the work, legal colleagues explain the conditions and finance explains the resources and reporting consequences. None of those accounts should quietly stand in for all the others.
There is also a portfolio consequence. If a company treats every conditional agreement amount as available funding, several individually plausible commitments can accumulate into an unfunded plan. The issue may remain hidden until one event moves or a payment condition is not met. I therefore review collaboration scenarios alongside the wider cash plan rather than evaluate each agreement in isolation. The board should be able to see how much of the intended activity relies on uncertain receipts and whether the same research event supports several optimistic assumptions at once.
I would regard the transaction as well explained when directors can value its potential without spending it twice in their minds: once as strategic opportunity and again as cash already in the bank. That requires an account of conditions, responsibilities and timing, not a smaller headline chosen merely to appear cautious. The USD60 million potential opportunity remained meaningful; the USD12 million receipt remained the immediate cash fact. Keeping both in their proper place helped the company accept a partnership ambitiously while funding its research with a clear view of what had actually become available.